DOCSLIB.ORG

1 Supplement Supplement Table 1. CD274 Loss, Neutral, and Gain in Various Diagnosis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1 Supplement Supplement Table 1. CD274 Loss, Neutral, and Gain in Various Diagnosis BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer Supplement Supplement Table 1. CD274 loss, neutral, and gain in various diagnosis CD274 CD274 CD274 Diagnosis N Loss Neutral Gain (%) (%) (%) lung adenocarcinoma 30396 48.5 36.3 15.1 colon adenocarcinoma (crc) 25618 19.3 55.6 25.0 breast carcinoma (nos) 14679 35.8 44.0 20.1 pancreas ductal adenocarcinoma 11698 56.3 35.2 8.5 prostate acinar adenocarcinoma 9466 28.6 55.0 16.4 lung squamous cell carcinoma (scc) 8852 52.6 29.5 17.9 breast invasive ductal carcinoma (idc) 8620 32.9 42.2 24.8 ovary serous carcinoma 7824 39.4 40.7 19.8 lung non-small cell lung carcinoma (nsclc) 6944 48.3 32.8 19.0 (nos) unknown primary adenocarcinoma 6329 48.2 38.0 13.8 rectum adenocarcinoma (crc) 5186 20.5 53.9 25.6 brain glioblastoma (gbm) 4787 36.1 54.6 9.3 liver cholangiocarcinoma 4653 48.0 39.8 12.2 bladder urothelial (transitional cell) 4443 42.0 39.6 18.4 carcinoma esophagus adenocarcinoma 4138 50.0 38.0 12.0 stomach adenocarcinoma (nos) 3979 40.6 45.0 14.4 head and neck squamous cell carcinoma 3511 31.0 43.3 25.7 (hnscc) skin melanoma 3501 55.4 36.6 8.1 unknown primary carcinoma (cup) (nos) 3432 41.1 40.2 18.7 uterus endometrial adenocarcinoma (nos) 3331 24.7 60.8 14.5 unknown primary melanoma 3038 51.4 37.7 11.0 ovary epithelial carcinoma 2564 37.7 41.8 20.5 lung small cell undifferentiated carcinoma 2493 21.4 51.6 27.0 pancreatobiliary carcinoma 2178 55.1 35.0 10.0 uterus endometrial adenocarcinoma 2113 16.6 71.7 11.7 endometrioid ovary high grade serous carcinoma 2025 41.1 37.8 21.1 uterus endometrial adenocarcinoma 1971 31.7 46.8 21.6 papillary serous kidney renal cell carcinoma 1675 48.2 40.1 11.7 gallbladder adenocarcinoma 1486 55.5 34.4 10.2 pancreas carcinoma (nos) 1481 55.1 34.4 10.5 gastroesophageal junction adenocarcinoma 1477 48.1 38.9 12.9 unknown primary squamous cell carcinoma 1414 39.7 36.8 23.6 (scc) 1 Huang RS.P, et al. J Immunother Cancer 2021; 9:e002680. doi: 10.1136/jitc-2021-002680 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer fallopian tube serous carcinoma 1383 40.2 38.2 21.6 breast invasive lobular carcinoma (ilc) 1340 18.2 66.1 15.7 cervix squamous cell carcinoma (scc) 1317 14.4 54.3 31.3 kidney clear cell carcinoma 1299 48.0 41.5 10.5 uterus carcinosarcoma 1255 42.4 43.3 14.3 liver hepatocellular carcinoma (hcc) 1230 24.6 63.4 12.0 unknown primary undifferentiated 1181 33.1 51.7 15.2 neuroendocrine carcinoma esophagus squamous cell carcinoma (scc) 1087 49.7 31.8 18.5 appendix adenocarcinoma 1009 16.4 59.4 24.3 thyroid papillary carcinoma 868 24.0 65.9 10.1 brain glioma (nos) 824 29.6 55.7 14.7 ovary clear cell carcinoma 811 33.2 54.5 12.3 lung large cell neuroendocrine carcinoma 770 43.8 37.3 19.0 anus squamous cell carcinoma (scc) 758 12.5 59.5 28.0 pleura mesothelioma 750 34 46.9 19.1 peritoneum serous carcinoma 738 39.6 41.2 19.2 skin squamous cell carcinoma (scc) 729 40.1 34.6 25.4 cervix adenocarcinoma 700 24.4 57.0 18.6 brain meningioma 700 16.6 74.6 8.9 pancreas islet cell tumor 691 25.5 46.3 28.2 brain anaplastic astrocytoma 653 38.6 49.9 11.5 bile duct adenocarcinoma 652 50.5 37.6 12.0 unknown primary urothelial carcinoma 647 46.7 36.9 16.4 small intestine adenocarcinoma 622 36.5 47.1 16.4 kidney urothelial carcinoma 620 43.5 40.0 16.5 unknown primary (nos) 570 36.0 43.7 20.4 brain astrocytoma 566 28.3 58.5 13.3 duodenum adenocarcinoma 562 41.1 43.2 15.7 ampullary adenocarcinoma 561 51.5 37.4 11.1 ovary endometrioid adenocarcinoma 540 24.3 57.8 18.0 unknown primary serous carcinoma 536 42.9 38.6 18.5 ovary carcinosarcoma 488 55.1 31.4 13.5 unknown primary gist 487 39.4 53.0 7.6 thyroid carcinoma (nos) 472 25.2 63.6 11.2 adrenal gland cortical carcinoma 424 27.1 48.3 24.5 vulva squamous cell carcinoma (scc) 423 21.5 44.9 33.6 unknown primary neuroendocrine tumor 422 31.8 54.7 13.5 thyroid anaplastic carcinoma 404 28.2 41.3 30.4 ovary granulosa cell tumor 371 16.2 71.2 12.7 ureter urothelial carcinoma 367 43.1 38.7 18.3 lung adenosquamous carcinoma 351 49.6 32.5 17.9 2 Huang RS.P, et al. J Immunother Cancer 2021; 9:e002680. doi: 10.1136/jitc-2021-002680 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer uterus endometrial adenocarcinoma clear 348 39.4 44.3 16.4 cell lung sarcomatoid carcinoma 347 34.9 32.3 32.9 stomach gist 346 37.6 54.6 7.8 salivary gland carcinoma (nos) 342 39.8 40.6 19.6 head and neck adenoid cystic carcinoma 340 17.4 61.8 20.9 prostate neuroendocrine carcinoma 340 29.7 49.7 20.6 brain oligodendroglioma 329 23.4 72.0 4.6 salivary gland adenoid cystic carcinoma 317 13.6 67.2 19.2 brain astrocytoma pilocytic 312 25.6 57.1 17.3 unknown primary undifferentiated small cell 304 27.3 53.6 19.1 carcinoma breast metaplastic carcinoma 297 32.3 42.8 24.9 skin merkel cell carcinoma 296 17.6 72.3 10.1 colon neuroendocrine carcinoma 289 24.6 61.9 13.5 esophagus carcinoma (nos) 287 44.6 38.0 17.4 bladder carcinoma (nos) 282 35.1 44.7 20.2 eye intraocular melanoma 279 24.0 64.5 11.5 thymus carcinoma 272 19.9 57.0 23.2 thyroid medullary carcinoma 271 35.8 56.8 7.4 kidney renal papillary carcinoma 269 37.5 53.9 8.6 salivary gland adenocarcinoma 252 42.5 44.4 13.1 peritoneum mesothelioma 244 23.0 59.0 18.0 brain medulloblastoma 243 14.8 68.7 16.5 neuroblastoma 243 32.9 58.4 8.6 stomach adenocarcinoma diffuse type 225 34.7 48.4 16.9 small intestine gist 218 23.9 67.0 9.2 penis squamous cell carcinoma (scc) 207 21.3 43.5 35.3 prostate undifferentiated carcinoma 194 31.4 46.4 22.2 brain ependymoma 193 20.2 51.3 28.5 soft tissue fibromatosis 191 25.7 65.4 8.9 skin basal cell carcinoma 190 17.9 56.8 25.3 uterus endometrial adenocarcinoma mixed 187 26.7 56.1 17.1 histology ovary carcinoma mixed histology 174 37.9 46.0 16.1 bladder adenocarcinoma 171 32.2 36.8 31.0 appendix goblet cell carcinoid (gcc) 171 18.7 57.9 23.4 lung large cell carcinoma 168 47.0 39.3 13.7 skin adnexal carcinoma 167 28.1 49.7 22.2 thyroid follicular carcinoma 165 16.4 68.5 15.2 ovary mucinous carcinoma 164 46.3 41.5 12.2 thymus thymoma (nos) 159 13.8 52.2 34.0 3 Huang RS.P, et al. J Immunother Cancer 2021; 9:e002680. doi: 10.1136/jitc-2021-002680 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer nasopharynx and paranasal sinuses 157 33.8 45.2 21.0 undifferentiated carcinoma bladder squamous cell carcinoma (scc) 156 37.2 37.8 25.0 salivary gland duct carcinoma 154 58.4 28.6 13.0 lung atypical carcinoid 151 26.5 63.6 9.9 unknown primary adenoid cystic carcinoma 144 18.8 62.5 18.8 unknown primary sarcomatoid carcinoma 141 30.5 34.8 34.8 vagina squamous cell carcinoma (scc) 141 21.3 50.4 28.4 head and neck melanoma 140 47.9 40.0 12.1 small intestine neuroendocrine carcinoma 140 25.0 67.1 7.9 bone chordoma 139 55.4 32.4 12.2 kidney carcinoma (nos) 136 46.3 41.2 12.5 testis germ cell tumor (non-seminoma) 133 26.3 57.1 16.5 ovary low grade serous carcinoma 131 35.1 58.8 6.1 prostate ductal adenocarcinoma 130 27.7 60.0 12.3 anus melanoma 129 58.1 34.9 7.0 appendix mucinous neoplasm 128 14.8 58.6 26.6 pancreas acinar cell carcinoma 128 53.1 34.4 12.5 salivary gland acinic cell tumor 125 8.0 73.6 18.4 rectum squamous cell carcinoma (scc) 119 21.8 47.1 31.1 brain anaplastic oligodendroglioma 117 35.9 57.3 6.8 nasopharynx and paranasal sinuses 115 26.1 49.6 24.3 squamous cell carcinoma (scc) fallopian tube adenocarcinoma 115 37.4 39.1 23.5 head and neck carcinoma (nos) 114 25.4 53.5 21.1 kidney sarcomatoid carcinoma 111 29.7 42.3 27.9 unknown primary carcinoid 110 34.5 53.6 11.8 soft tissue sarcoma (nos) 109 37.6 44.0 18.3 stomach adenocarcinoma intestinal type 105 40.0 45.7 14.3 kidney wilms tumor 104 12.5 68.3 19.2 cervix neuroendocrine carcinoma 101 18.8 65.3 15.8 peritoneum adenocarcinoma 100 37.0 44.0 19.0 bladder small cell carcinoma 95 21.1 51.6 27.4 paraganglioma 95 11.6 73.7 14.7 lung adenoid cystic carcinoma 94 14.9 63.8 21.3 small intestine carcinoid 92 32.6 62.0 5.4 uterus leiomyosarcoma 91 31.9 50.5 17.6 esophagus neuroendocrine carcinoma 90 36.7 46.7 16.7 brain gliosarcoma 87 36.8 54.0 9.2 vulva melanoma 87 60.9 31.0 8.0 salivary gland mucoepidermoid carcinoma 85 24.7 49.4 25.9 rectum neuroendocrine carcinoma 84 10.7 66.7 22.6 soft tissue leiomyosarcoma 84 36.9 47.6 15.5 4 Huang RS.P, et al.
Load more

Recommended publications
  • PROPOSED REGULATION of the STATE BOARD of HEALTH LCB File No. R057-16
    PROPOSED REGULATION OF THE STATE BOARD OF HEALTH LCB File No. R057-16 Section 1. Chapter 457 of NAC is hereby amended by adding thereto the following provision: 1. The Division may impose an administrative penalty of $5,000 against any person or organization who is responsible for reporting information on cancer who violates the provisions of NRS 457. 230 and 457.250. 2. The Division shall give notice in the manner set forth in NAC 439.345 before imposing any administrative penalty 3. Any person or organization upon whom the Division imposes an administrative penalty pursuant to this section may appeal the action pursuant to the procedures set forth in NAC 439.300 to 439. 395, inclusive. Section 2. NAC 457.010 is here by amended to read as follows: As used in NAC 457.010 to 457.150, inclusive, unless the context otherwise requires: 1. “Cancer” has the meaning ascribed to it in NRS 457.020. 2. “Division” means the Division of Public and Behavioral Health of the Department of Health and Human Services. 3. “Health care facility” has the meaning ascribed to it in NRS 457.020. 4. “[Malignant neoplasm” means a virulent or potentially virulent tumor, regardless of the tissue of origin. [4] “Medical laboratory” has the meaning ascribed to it in NRS 652.060. 5. “Neoplasm” means a virulent or potentially virulent tumor, regardless of the tissue of origin. 6. “[Physician] Provider of health care” means a [physician] provider of health care licensed pursuant to chapter [630 or 633] 629.031 of NRS. 7. “Registry” means the office in which the Chief Medical Officer conducts the program for reporting information on cancer and maintains records containing that information.
    [Show full text]
  • Variants of Acinar Adenocarcinoma of the Prostate Mimicking Benign Conditions Peter a Humphrey
    Modern Pathology (2018) 31, S64–S70 S64 © 2018 USCAP, Inc All rights reserved 0893-3952/18 $32.00 Variants of acinar adenocarcinoma of the prostate mimicking benign conditions Peter A Humphrey Department of Pathology, Yale School of Medicine, New Haven, CT, USA Histological variants of acinar adenocarcinoma of the prostate may be of significance due to difficulty in diagnosis or due to differences in prognosis compared to usual acinar adenocarcinoma. The 2016 World Health Organization classification of acinar adenocarcinoma includes four variants that are deceptively benign in histological appearance, such that a misdiagnosis of a benign condition may be made. These four variants are atrophic pattern adenocarcinoma, pseudohyperplastic adenocarcinoma, microcystic adenocarcinoma, and foamy gland adenocarcinoma. They differ from usual small acinar adenocarcinoma in architectural glandular structure and/or cytoplasmic and nuclear alterations. The variants are often admixed, in variable proportions, with usual small acinar adenocarcinoma that is often Gleason pattern 3 but may be high-grade pattern 4 in a minority of cases. Atrophic pattern adenocarcinoma can be identified in a sporadic setting or after radiation or hormonal therapy. This variant is characterized by cytoplasmic volume loss and can resemble benign glandular atrophy, an extremely common benign process in the prostate. The glands of pseudohyperplastic adenocarcinoma simulate usual epithelial hyperplasia, with gland complexity that is not typical of small acinar adenocarcinoma. These complex growth configurations include papillary infoldings, luminal undulations, and branching. Microcystic adenocarcinoma is characterized by cystic dilation of prostatic glands to a size that is much more commonly observed in cystic change in benign prostatic glands. Finally, the cells in foamy gland adenocarcinoma display cytoplasmic vacuolization and nuclear pyknosis, features that can found in benign glands and macrophages.
    [Show full text]
  • Supplementary Table 1) Immunohistochemical Protocol and Antibody Information Antibody Company Clone/# Clonality Dilution Incubat
    H. Reis et al: Differential proteomic and tissue expression analyses identify valuable diagnostic biomarkers of hepatocellular differentiation and hepatoid adenocarcinomas Suppl ementary Table 1) Immunohistochemical protocol and antibody information Antibody Company Clone/# Clonality Dilution Incubation Antigen retrieval Detection ABAT Abcam EPR4433 mono 1/3000 30 min, RT pH 9.0, WB, 95°C, 20 min. Zytomed Polymer HRP ACAA2 Abcam EPR6733 mono 1/100 30 min, RT pH 9.0, WB, 95°C, 20 min Zytomed Polymer HRP ACADM Abcam EPR3708 mono 1/3000 30 min, RT pH 9.0, WB, 95°C, 20 min Zytomed Polymer HRP ADH1B Abcam 4F12 mono 1/12.000 30 min, RT pH 9.0, WB, 95°C, 20 min Zytomed Polymer HRP Arginase1 Abcam EPR6672(B) mono 1/1000 30 min, RT pH 9.0, WB, 95°C, 20 min. Zytomed Polymer HRP BHMT Abcam EPR6782 mono 1/100 30 min, RT pH 9.0, WB, 95°C, 20 min. Zytomed Polymer HRP FABP1 Acris AIV\09011PU-S mono 1/15.000 30 min, RT pH 9.0, WB, 95°C, 20 min. Zytomed Polymer HRP HAOX1 Acris AP18044PU-N poly 1/100 30 min, RT pH 9.0, WB, 95°C, 20 min. Zytomed Polymer HRP HepPar1 Dako OCH1E5 mono 1/800 30 min, RT pH 9.0, WB, 95°C, 20 min. Zytomed Polymer HRP HMGCS2 Abcam Ab104807 poly 1/50 60 min, RT pH 9.0, WB, 95°C, 20 min Zytomed Polymer HRP H. Reis et al: Differential proteomic and tissue expression analyses identify valuable diagnostic biomarkers of hepatocellular differentiation and hepatoid adenocarcinomas Supplementary Table 2) Composition of the non-liver tumor TMA Diagnosis n % ADC 11 2.9 ADC Adenocarcinoma of the lung Carc.
    [Show full text]
  • 1 Effective January 1, 2018 ICD‐O‐3 Codes, Behaviors and Terms Are Site‐Specific Alpha Order Last Updat
    Effective January 1, 2018 ICD‐O‐3 codes, behaviors and terms are site‐specific Alpha Order Last updated 8/22/18 Status ICD‐O‐3 Term Reportable Comments Morphology Y/N Code New Term 8551/3 Acinar adenocarcinoma (C34. _) Y Lung primaries diagnosed prior to 1/1/2018 use code 8550/3 For prostate (all years) see 8140/3 New Term 8140/3 Acinar adenocarcinoma (C61.9 ONLY) Y For prostate only, do not use 8550/3 New Term 8572/3 Acinar adenocarcinoma, sarcomatoid (C61.9) Y New Term 8550/3 Acinar cell carcinoma Y Excludes C61.9‐ see 8140/3 New Term 8316/3 Acquired cystic disease‐associated renal cell carcinoma (RCC) Y (C64.9) New 8158/1 ACTH‐producing tumor N code/term New Term 8574/3 Adenocarcinoma admixed with neuroendocrine carcinoma (C53. _) Y Behavior 8253/2 Adenocarcinoma in situ, mucinous (C34. _) Y Important note: lung Code/term primaries ONLY: For cases diagnosed 1/1/2018 forward do not use code 8480 (mucinous adenocarcinoma) for in‐ situ adenocarcinoma, mucinous or invasive mucinous adenocarcinoma. 1 Status ICD‐O‐3 Term Reportable Comments Morphology Y/N Code Behavior 8250/2 Adenocarcinoma in situ, non‐mucinous (C34. _) Y code/term New Term 9110/3 Adenocarcinoma of rete ovarii (C56.9) Y New 8163/3 Adenocarcinoma, pancreatobiliary‐type (C24.1) Y Cases diagnosed prior to code/term 1/1/2018 use code 8255/3 Behavior 8983/3 Adenomyoepithelioma with carcinoma (C50. _) Y Code/term New Term 8620/3 Adult granulosa cell tumor (C56.9 ONLY) N Not reportable for 2018 cases New Term 9401/3 Anaplastic astrocytoma, IDH‐mutant (C71.
    [Show full text]
  • December 2020 E-Tips Solid Tumor Rules
    New Jersey State Cancer Registry December 2020 E-Tips Cancer Epidemiology Services http://www.nj.gov/health/ces (609) 633-0500 Solid Tumor Rules: December 2020 Update ICD-0-3.2 changes have also been added to applicable site modules. Most changes are minor: terminology, additional definitions, new notes and examples. In order to clarify histology coding instructions, new rules have been added and histology tables updated. These updates do not require review of already abstracted cases. The December 2020 rules replace the current rules and should be used now. SEER Strongly recommends reading the December 2020 Change Log to understand what changes were made. The updated Solid Tumor Rules may be accessed at: https://seer.cancer.gov/tools/solidtumor/ Reportability Changes for 2021 Radiation Coding Total Dose (1533) Starting 01/01/2021 the following terms are reportable: If doses across phases to a single point of region, code Sum of all phases. ** (see 2019 update below) Early or evolving melanoma in situ, or any other early or If doses are to multiple metastatic sites, code highest evolving melanoma, are reportable. dose site. If doses are to primary site and metastatic site, code dose All GIST tumors are reportable and classified as 8936/3 in from the primary site only. ICD-O-3.2. When you have two different sites, you cannot add the Nearly all thymomas are reportable; the exceptions are doses together to get the total dose. microscopic thymoma or thymoma benign (8580/0), micronodular thymoma with lymphoid stroma (8580/1), Radiation Tips and updates for 2019 and ectopic hamartomatous thymoma (8587/0).
    [Show full text]
  • Updated 1/10/18 Effective January 1, 2018 ICD‐O‐3 Codes, Behaviors and Terms Are Site‐Specific Status IC
    Effective January 1, 2018 ICD‐O‐3 codes, behaviors and terms are site‐specific Status ICD‐O‐3 Term Reportable Comments Morphology Y/N Code New Term 8010/3 Urachal carcinoma (C65.9, C66.9, C67. _, C68._) Y New Term 8013/3 Combined large cell neuroendocrine carcinoma (C34. _, C37.9) Y New 8023/3 Midline carcinoma of children and young adults with NUT Y code/term rearrangement (C30.0, C31.9, C34. _) New 8023/3 NUT carcinoma (C30.0, C31.9, C34. _) Y code/term New 8023/3 NUT midline (C30.0, C31.9, C34. _) Y code/term New Term 8041/3 High‐grade neuroendocrine carcinoma (C54. _, C55.9) Y New Term 8041/3 Neuroendocrine carcinoma, poorly differentiated (C50. _) Y New Term 8041/3 Small cell carcinoma pulmonary type (C56.9) Y New Term 8044/3 Small cell carcinoma, hypercalcemic type (C56.9) Y New 8054/3 Condylomatous carcinoma (C60.0‐C60.2, C60.9) Y Cases diagnosed prior to code/term 1/1/2018 use code 8051/3 All other sites use 8051/3 2018 forward New 8054/3 Warty carcinoma (C60.0‐C60.2, C60.9) Y Cases diagnosed prior to code/term 1/1/2018 use code 8051/3 All other sites use 8051/3 2018 forward Behavior 8071/2 Differentiated penile intraepithelial neoplasia (C60. _) N Not reportable for 2018 code/term Behavior 8071/2 Differentiated‐type vulvar intraepithelial neoplasia (C51. _) N Not reportable for 2018 code/term New 8085/3 Squamous cell carcinoma, HPV‐positive (C01.9, C10.2, C10.3, C10.8, Y code/term C10.9, C31.0–C31.3, C31.9) Updated 1/10/18 Status ICD‐O‐3 Term Reportable Comments Morphology Y/N Code New 8086/3 Squamous cell carcinoma, HPV‐negative (C01.9, C10.2, C10.3, Y code/term C10.8, C10.9, C31.0–C31.3, C31.9) New Term 8120/3 Clear cell (glycogen‐rich) urothelial carcinoma (C65.9, C66.9, C67.
    [Show full text]
  • List of Acceptable TCGA Tumor Types*
    List of Acceptable TCGA Tumor Types* Acute Myeloid Leukemia Head and Neck Squamous ** Ovarian Carcinoma** Thyroid Papillary Carcinoma** Squamous Cell Carcinoma Serous Cystadenocarcinoma Papillary, Usual Type (Papillary, NOS) Bladder Urothelial Carcinoma Squamous Cell Carcinoma, Spindle Cell Variant Serous carcinoma Papillary, Follicular Variant (99% follicular patterned) Muscle invasive urothelial carcinoma (PT2 or above) Squamous Cell Carcinoma, Basaloid Type Serous adenocarcinoma Papillary, Tall cell Variant (50% tall cell features) Papillary Serous carcinoma Papillary, Other Breast Invasive Carcinoma Hepatocellular Carcinoma Papillary Serous cystoadenocarcinoma Infiltrating Ductal Carcinoma** Hepatocellular Carcinoma, NOS Serous Papillary carcinoma Rare Tumor Studies Infiltrating Lobular Carcinoma Fibrolamellar Hepatocellular Carcinoma Serous Papillary cystoadenocarcinoma Medullary Carcinoma Hepatocholangiocarcinoma (mixed) Serous Papillary adenocarcinoma Adrenocortcal Tumors*** Mucinous Carcinoma Adrenocortical carcinoma - Usual Type Metaplastic Carcinoma Kidney Adenocarcinoma Pancreatic Adenocarcinoma Adrenocortical carcinoma - Oncocytic Type Mixed (with Ductal) Histology*** Clear Cell Renal Cell Carcinoma** Adenocarcinoma, ductal type Adrenocortical carcinoma - Myxoid Type Other Papillary Renal Cell Carcinoma Colloid (mucinous non-cystic) Carcinoma Hepatoid Carcinoma Chromophobe Kidney*** Cervical Cancer Lower Grade Glioma** Medullary Carcinoma Cervical Squamous Cell Carcinoma Astrocytoma, Grade II Signet Ring Cell Carcinoma Mesothelioma
    [Show full text]
  • Two Cases of Solitary Fibrous Tumor Involving Urinary Bladder and a Review of the Literature
    Hindawi Publishing Corporation Case Reports in Urology Volume 2016, Article ID 5145789, 5 pages http://dx.doi.org/10.1155/2016/5145789 Case Report Two Cases of Solitary Fibrous Tumor Involving Urinary Bladder and a Review of the Literature Eduardo Yukio Tanaka,1,2 Vitor Bonadia Buonfiglio,1,2 Joao Padua Manzano,1,2 Renée Zon Filippi,2 and Marcus Vinicius Sadi1,2 1 Federal University of Sao˜ Paulo, Sao˜ Paulo, SP, Brazil 2Hospital Israelita Albert Einstein, Sao˜ Paulo, SP, Brazil Correspondence should be addressed to Eduardo Yukio Tanaka; du [email protected] Received 12 June 2016; Revised 5 September 2016; Accepted 8 September 2016 Academic Editor: Fumitaka Koga Copyright © 2016 Eduardo Yukio Tanaka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Solitary fibrous tumor (SFT) is a rare neoplasia of mesenchymal origin, initially described in visceral pleura and lately discovered to have ubiquitous distribution. SFT of the urogenital tract is uncommon and appears to have similar morphologic features and biologic behaviors as SFTs found elsewhere. We present two new cases of SFT of the bladder and review 22 similar cases published in the literature. Due to the general indolent behavior of these lesions, a complete but organ sparing surgical excision should be considered when technically feasible. Therefore, proper identification and characterization of SFT through morphological and immunohistochemical criteria on biopsy specimens are mandatory in the differential diagnosis from other more aggressive spindle- cell tumors, thus avoiding unnecessary radical surgery.
    [Show full text]
  • Labinvest201321.Pdf
    190A ANNUAL MEETING ABSTRACTS Sensitivity, specificity, positive/negative predictive value, and the odds ratio of the SCC (0/33) by FISH. No difference of overall survival time was observed between 2 markers were summarized in Table 1. There was no difference in p16 expression amplified and non-amplified groups in EAC patients. between the DG and control group. Conclusions: ALK amplification was present in 7% of EAC cases, but ALK Table 1. Summary of sensitivity, specificity, PPV, NPV, and OR. rearrangement and expression was not present. No ALK amplification, rearrangement Sensitivity (%) Specificity (%) PPV (%) NPV (%) OR and expression were detected in SCC. ALK amplification is not associated with EAC beta-catenin 92.3 76.9 80.0 90.9 40.0 patients’ overall survival. c-met 69.2 61.5 64.3 66.7 3.6 Either 100.0 53.8 68.4 100.0 13.9* Both 61.5 92.3 88.9 70.6 19.2 785 Mitosis-Specific Marker PHH3 Immunostain Is a More Sensitive NPV, negative predictive value; PPV, positive predictive value; OR, odds ratio. *, estimated OR. and Efficient Method To Evaluate the Mitotic Activity in Gastrointestinal Conclusions: The combination of c-met and beta-catenin provides a relatively specific Stromal Tumor (GIST) panel to identify patients with BE who are at increased risk for future development S Zhu, F Lin, ZE Chen. Geisinger Medical Center, Danville, PA. of dysplasia. Background: Mitotic activity is an important prognostic factor in GIST. The accurate identification of mitotic figures on the H&E stained slides could be challenging due to 783 Microfibrillar Associated Protein 5 (MFAP 5): A Marker for processing artifact, degeneration, apoptosis, or lymphocytic infiltration.
    [Show full text]
  • Pulmonary in Trisomy 18 (T18) and Has Been Described Also in Several Disorders Other Than T18
    ANNUAL MEETING ABSTRACTS 449A 1867 Infections in a Children’s Hospital Autopsy Population abstract, is useful and may serve as a guideline to define CH, with linear regression +20% J Springer, R Craver. Louisiana State University Health Science Center, New Orleans, of T18 cases and/or linear regression -20% of control cases being the borderline for CH. LA. Background: Despite advances in antimicrobial therapy, infections/inflammatory 1869 Expression of Disialoganglioside GD2 in Neuroblastomas of lesions may frequently cause or contribute to death in children. Patients Treated with Immunotherapy Design: We retrospectively reviewed all autopsies performed at a children’s hospital T Terzic, P Teira, S Cournoyer, M Peuchmaur, H Sartelet. Centre Hospitalier from 1986-2009 and categorized infectious complications as 1)underlying cause Universitaire Sainte-Justine, Montreal, QC, Canada; Hopital Universitaire Robert- of death,2) mechanism of death complicating another underlying cause of death,3) Debre, Paris, France. contributing to death 4) agonal or infections immediately before death 5) incidental. Background: Neuroblastoma, a malignant neoplasm of the sympathetic nervous Infectious complications were then separated into 3-8 year groups to identify trends system, is one of the most aggressive pediatric cancers with a tendency for widespread over the years. dissemination, relapse and a poor long term survival, despite intensive multimodal Results: There were 1369 deaths over 24 years, 608 (44%) underwent autopsy at treatments. Recent use of immunotherapy (a chimeric human-murine monoclonal the hospital, another 122 (8.9%) were coroner’s cases not performed at the hospital. antibody ch14.18 directed against a tumor-associated antigen GD2, a disialoganglioside) There were 691 infectious conditions in 401 children (66%, 1.72 infections/infected to treat minimal residual disease has shown improvement in event-free and overall patient).There were no differences in the percentage of autopsies with infections over survival of high-risk neuroblastomas.
    [Show full text]
  • Comparison of Tumour Markers in Malignant Mesothelioma and Pulmonary Adenocarcinoma
    Thorax: first published as 10.1136/thx.40.2.91 on 1 February 1985. Downloaded from Thorax 1985;40:91-95 Comparison of tumour markers in malignant mesothelioma and pulmonary adenocarcinoma AR GIBBS, R HARACH, JC WAGNER, B JASANI From the Pathology Department, Welsh National School, Cardiff, and the Medical Research Council Pneumoconiosis Unit, Llandough Hospital, Penarth, Glamorgan ABSTRACr Immunohistological methods were used to investigate the presence of carcinoem- bryonic antigen, ,31 pregnancy specific glycoprotein, /8 subunit of human chorionic gonado- trophin, human placental lactogen, calcitonin, and keratin in formalin fixed tissue from 29 malig- nant mesotheliomas and 27 pulmonary adenocarcinomas. Malignant mesotheliomas were nega- tive for tumour markers except for the ,8 subunit of human chorionic gonadotrophin and keratin, one and 13 cases respectively being positive for these. Pulmonary adenocarcinomas, however, were frequently positive for tumour markers-namely, carcinoembryonic antigen (24), ,3B preg- nancy specific glycoprotein (23), ,8 subunit of human chorionic gonadotrophin (8), human placen- tal lactogen (2), calcitonin (3), and keratin (12). The presence of carcinoembryonic antigen and ,/3 pregnancy specific glycoprotein within an intrathoracic tumour is strong evidence against its being of mesothelial origin. copyright. The accurate diagnosis of malignant tumours is an needs to be recognised well in advance, so that the essential part of the management of patients, but for appropriate fixation and embedding techniques
    [Show full text]
  • TNM Classification of Malignant Tumours
    Table of Contents Cover Title Page Preface References Acknowledgments Organizations Associated with the TNM System Members of UICC Committees Associated with the TNM System Section Editors Introduction References Head and Neck Tumours Lip and Oral Cavity Pharynx References Larynx Nasal Cavity and Paranasal Sinuses Unknown Primary – Cervical Nodes Malignant Melanoma of Upper Aerodigestive Tract Major Salivary Glands Thyroid Gland Digestive System Tumours Oesophagus Stomach Reference Small Intestine Appendix Colon and Rectum Anal Canal and Perianal Skin Liver Intrahepatic Bile Ducts Gallbladder Perihilar Bile Ducts Distal Extrahepatic Bile Duct Ampulla of Vater Pancreas Well Differentiated Neuroendocrine Tumours of the Gastrointestinal Tract Lung, Pleural, and Thymic Tumours Lung References Pleural Mesothelioma Thymic Tumours References Tumours of Bone and Soft Tissues Bone Soft Tissues Gastrointestinal Stromal Tumour (GIST) Skin Tumours Carcinoma of Skin (excluding eyelid, head and neck, perianal, vulva, and penis) Skin Carcinoma of the Head and Neck Carcinoma of Skin of the Eyelid Malignant Melanoma of Skin Merkel Cell Carcinoma of Skin Breast Tumours Reference Gynaecological Tumours Reference Vulva Vagina Cervix Uteri Uterus – Endometrium Reference Uterine Sarcomas References Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Reference Gestational Trophoblastic Neoplasms Reference Urological Tumours Penis Prostate References Testis Kidney Renal Pelvis and Ureter Urinary Bladder Urethra Adrenal Cortex (ICD O 3 C74.0) Ophthalmic
    [Show full text]